2005, Clinical Trials, Epilepsy and Terpenes

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2005

Clinical Trials

Epilepsy

Terpenes

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Fig 1: Sucralose (In Study).

Extraction

Extraction Pharmaceutical CBD Epilepsy

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Conclusions. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ).

Research and Development

Research and Development Medicine Access Media

Medical Cannabis Brief

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Stay Connected